GO:0047224 acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047224 describes the enzymatic activity that transfers N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to a GalNAc residue already attached to a protein, forming the core 3 O-glycan structure.
• This activity is catalyzed by core 3 beta3-GlcNAc-transferase, historically measured in colonic mucosa and other tissues.
• The reaction is a beta-1,3 linkage between GlcNAc and GalNAc-O-Ser/Thr, a key step in mucin-type O-glycosylation.
• Loss of this activity has been observed in human cancer cell lines, suggesting a role in tumor biology.
• The enzyme uses UDP-GlcNAc as the donor substrate and a GalNAc-alpha-O-Ser/Thr protein as the acceptor.
• Studying GO:0047224 helps understand mucin biosynthesis, cell surface glycosylation, and cancer-associated glycosylation changes.
Description
GO:0047224, acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity, is a molecular function that catalyzes the transfer of N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to a GalNAc residue already O-linked to a serine or threonine on a protein, forming a beta-1,3 linkage. This reaction produces the core 3 O-glycan structure, which is one of the major mucin-type O-glycan cores found in secreted and membrane-bound glycoproteins. The activity was first characterized biochemically in pig and rat colon mucosa, where it was shown to elongate GalNAc-alpha-O-R acceptors. Later work confirmed the presence of this activity in human colonic mucosal tissues but noted its absence in several human cancer cell lines, suggesting that loss of core 3 synthesis may be a feature of malignant transformation. Researchers study this activity to understand mucin biosynthesis, epithelial barrier function, and the altered glycosylation patterns observed in cancer and inflammatory diseases.
acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity At A Glance
| GO ID | GO:0047224 |
|---|---|
| GO term | acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity |
| Ontology | molecular_function |
| Synonym | core 3-beta-GlcNAc-transferase activity; core 3beta-GlcNAc-transferase activity; mucin core 3 beta3-GlcNAc-transferase activity; O-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase III activity; UDP-N-acetyl-D-glucosamine:O-glycosyl-glycoprotein (N-acetyl-D-glucosamine to N-acetyl-D-galactosaminyl-R) beta-1,3-N-acetyl-D-glucosaminyltransferase activity; uridine diphosphoacetylglucosamine-mucin beta(1->3)-acetylglucosaminyltransferase activity |
| Major function | Catalyzes the transfer of GlcNAc from UDP-GlcNAc to GalNAc-O-Ser/Thr on proteins, forming core 3 O-glycans. |
| Reaction | 3-O-N-acetyl-D-galactosalaminyl-[protein] + UDP-N-acetyl-D-glucosamine = 3-O-N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-D-galactosaminyl-[protein] + UDP. |
| Substrates | UDP-N-acetyl-D-glucosamine (donor); GalNAc-O-Ser/Thr protein (acceptor). |
| Products | GlcNAc-beta-1,3-GalNAc-O-Ser/Thr protein; UDP. |
| Linkage | Beta-1,3 linkage between GlcNAc and GalNAc; glycan attached to protein via oxygen of Ser/Thr. |
What Is GO:0047224?
This GO term describes an enzymatic activity that adds a GlcNAc sugar to a GalNAc sugar already attached to a protein. Specifically, it catalyzes the reaction: 3-O-N-acetyl-D-galactosalaminyl-[protein] + UDP-N-acetyl-D-glucosamine = 3-O-N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-D-galactosaminyl-[protein] + UDP. The linkage formed is a beta-1,3 bond between GlcNAc and GalNAc, and the GalNAc is linked to the protein via the oxygen atom of a serine or threonine side chain. This activity is also known as core 3-beta-GlcNAc-transferase or mucin core 3 beta3-GlcNAc-transferase.
Why Is acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity Important in Cell Biology?
GO:0047224 is important because it initiates the synthesis of core 3 O-glycans, a major class of mucin-type glycans that contribute to the protective mucus layer of the gastrointestinal tract and influence cell-cell interactions. The activity is developmentally and tissue-specifically regulated, and its loss has been linked to cancer, as several human cancer cell lines lack detectable core 3 beta3-GlcNAc-transferase activity. Understanding this enzyme helps explain how normal epithelial cells maintain their glycosylation patterns and how these patterns change in disease, potentially offering targets for diagnosis or therapy.
• Core 3 O-glycans are abundant in mucins and contribute to the viscoelastic properties of mucus.
• The enzyme is highly expressed in colonic mucosa, where it helps maintain the epithelial barrier.
• Loss of core 3 beta3-GlcNAc-transferase activity is observed in human cancer cell lines, suggesting a tumor-suppressive role.
• Altered O-glycosylation is a hallmark of many cancers and inflammatory diseases.
• The activity influences the structure of cell surface glycoproteins involved in signaling and adhesion.
• Studying this enzyme can reveal mechanisms of glycan-mediated host-pathogen interactions.
• It provides a potential biomarker for colon cancer and other malignancies.
• Understanding its regulation may lead to new therapeutic strategies targeting glycosylation.
What Happens During acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme first grabs the sugar donor and the protein target.
The enzyme binds UDP-GlcNAc as the donor substrate and a GalNAc-alpha-O-Ser/Thr protein as the acceptor. The GalNAc residue is already attached to the protein by a previous glycosyltransferase. The enzyme recognizes the GalNAc moiety and positions it for catalysis.
Catalytic transfer of GlcNAc
In simple terms: The enzyme snaps a GlcNAc sugar onto the existing GalNAc sugar.
The enzyme catalyzes the transfer of GlcNAc from UDP-GlcNAc to the C3 hydroxyl group of GalNAc, forming a beta-1,3 linkage. This reaction releases UDP. The product is GlcNAc-beta-1,3-GalNAc-O-Ser/Thr, which is the core 3 O-glycan structure.
Formation of core 3 O-glycan
In simple terms: The new sugar structure becomes a core 3 glycan, a building block for larger glycans.
The addition of GlcNAc to GalNAc creates the core 3 structure, which can be further elongated by other glycosyltransferases to form complex mucin-type O-glycans. This core structure is distinct from cores 1, 2, and 4, and its synthesis is often tissue-specific.
Tissue distribution and regulation
In simple terms: This enzyme is active mainly in certain tissues like the colon.
The activity was first detected in pig and rat colon mucosa, and later in human colonic mucosal tissues. However, it is absent in several human cancer cell lines, indicating that its expression is regulated and can be lost during malignant transformation.
Key Genes Involved in GO:0047224 acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity
The following genes and proteins are directly or indirectly associated with GO:0047224 activity, based on biochemical and tissue studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| B3GNT6 | Encodes core 3 beta3-GlcNAc-transferase, the enzyme responsible for GO:0047224 activity | Main gene for studying core 3 O-glycan synthesis; mutations linked to cancer |
| GALNT1 | Initiates O-glycosylation by adding GalNAc to Ser/Thr | Provides the acceptor substrate for core 3 synthesis |
| GALNT2 | Adds GalNAc to specific protein sites | May influence core 3 formation by generating GalNAc-O-Ser/Thr acceptors |
| GALNT3 | O-glycosyltransferase | Contributes to the pool of GalNAc-modified proteins |
| GALNT4 | O-glycosyltransferase | Affects O-glycan initiation and core 3 substrate availability |
| GALNT5 | O-glycosyltransferase | Tissue-specific roles in mucin glycosylation |
| GALNT6 | O-glycosyltransferase | May compete with core 3 synthesis |
| GALNT7 | O-glycosyltransferase | Influences O-glycan branching |
| GALNT10 | O-glycosyltransferase | Expressed in colon; may affect core 3 |
| C1GALT1 | Synthesizes core 1 O-glycans | Competes with core 3 pathway |
| C1GALT1C1 | Chaperone for C1GALT1 | Regulates core 1 synthesis, indirectly affecting core 3 |
| GCNT1 | Synthesizes core 2 O-glycans | Uses core 1 as substrate; may compete with core 3 |
| GCNT3 | Synthesizes core 4 O-glycans | Uses core 3 as substrate for elongation |
| ST3GAL1 | Sialyltransferase | Modifies O-glycans, affecting core 3 processing |
| ST6GALNAC1 | Sialyltransferase | Adds sialic acid to GalNAc, blocking core 3 synthesis |
| B3GNT3 | Related beta-1,3-N-acetylglucosaminyltransferase | May have overlapping functions |
| B3GNT8 | Related beta-1,3-N-acetylglucosaminyltransferase | Potential redundancy in core 3 synthesis |
| UDP-GlcNAc | Donor substrate | Metabolic pathways supplying UDP-GlcNAc affect enzyme activity |
How Is acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity Regulated?
The activity of core 3 beta3-GlcNAc-transferase is regulated at multiple levels. Its expression is tissue-specific, with high activity in colonic mucosa but low or absent in other tissues. In cancer cell lines, the activity is often lost, suggesting epigenetic or genetic silencing. The enzyme competes with other glycosyltransferases such as C1GALT1 (core 1 synthase) and ST6GALNAC1 (sialyltransferase) for the common GalNAc-O-Ser/Thr acceptor, so the relative expression levels of these enzymes determine the proportion of core 3 structures. Additionally, the availability of UDP-GlcNAc, which is influenced by cellular metabolism, can affect the reaction rate.
acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B3GNT6 | Colon cancer, loss of core 3 O-glycans | Knockout in HCT116 or Caco-2 cells; overexpression in cancer cell lines |
| GALNT1 | Altered O-glycosylation in cancer | Point mutation to modify acceptor site usage |
| C1GALT1 | Competition with core 3 pathway | Knockout to shift glycan profiles |
| ST6GALNAC1 | Sialylation blocking core 3 synthesis | Overexpression to reduce core 3 |
| GCNT3 | Core 4 synthesis from core 3 | Knock-in of tagged enzyme to track elongation |
Cancer
Loss of core 3 beta3-GlcNAc-transferase activity has been observed in human cancer cell lines, including colon cancer lines, suggesting that downregulation of this enzyme contributes to altered glycosylation in tumors. Core 3 O-glycans are thought to play a role in cell adhesion and signaling, and their absence may promote malignant behavior.
Inflammatory bowel disease
Altered mucin glycosylation, including changes in core 3 structures, has been associated with inflammatory bowel diseases, although direct evidence for GO:0047224 in this context is limited.
Colon cancer
The enzyme is highly expressed in normal colonic mucosa, but its activity is reduced or absent in colon cancer cell lines, indicating a potential tumor-suppressive role for core 3 O-glycans.
From acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of B3GNT6 promote tumorigenesis? | B3GNT6 knockout in colon cancer cell lines and mouse xenografts |
| What is the substrate specificity of core 3 beta3-GlcNAc-transferase? | Point mutations in B3GNT6 catalytic domain, expressed in HEK293 cells |
| Can core 3 O-glycans be restored in cancer cells? | Knock-in of B3GNT6 into cancer cell lines lacking activity |
| Where is the enzyme localized in cells? | Tagged knock-in of B3GNT6 with GFP in colonic epithelial cells |
| Does overexpression of B3GNT6 alter cell adhesion? | Overexpression in cancer cell lines followed by adhesion assays |
| What genes regulate core 3 synthesis? | CRISPR library screening in colon organoids |
How to Study the acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay with radiolabeled UDP-GlcNAc | Core 3 beta3-GlcNAc-transferase activity | Characterization of enzyme kinetics and tissue distribution |
| Mass spectrometry of O-glycans | Presence of core 3 structures | Comparing normal vs cancer cells |
| CRISPR knockout screening | Genes affecting core 3 synthesis | Identifying regulators of glycosylation |
| Lectin histochemistry | Localization of core 3 O-glycans | Tissue microarray analysis of cancer |
| Western blot | Expression of B3GNT6 protein | Correlating expression with activity |
| RT-qPCR | mRNA levels of B3GNT6 and related genes | Gene expression profiling |
| Flow cytometry | Cell surface core 3 glycans | Analyzing live cells |
| Glycosyltransferase overexpression | Effects on glycan profile | Functional studies in cell lines |
Enzymatic activity assays
Core 3 beta3-GlcNAc-transferase activity is typically measured using radiolabeled UDP-[3H]GlcNAc and a GalNAc-O-Ser/Thr acceptor, followed by product separation by chromatography. This method was used to characterize the enzyme in colonic mucosa.
Glycan profiling by mass spectrometry
Mass spectrometry of released O-glycans can reveal the presence or absence of core 3 structures in cells and tissues, providing a readout of enzyme activity.
CRISPR-Cas9 knockout screens
Genome-wide knockout screens can identify genes that regulate core 3 O-glycan synthesis, including B3GNT6 and competing glycosyltransferases.
Immunohistochemistry and lectin staining
Lectin staining with core 3-specific lectins can localize core 3 O-glycans in tissues and assess changes in expression in cancer.
How CRISPR Can Be Used to Study GO:0047224 acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity
Knockout
CRISPR-Cas9 knockout of B3GNT6 can eliminate core 3 beta3-GlcNAc-transferase activity, allowing researchers to study the consequences of losing core 3 O-glycans on cell behavior, adhesion, and tumorigenicity.
Point Mutation
Introducing point mutations in the catalytic domain of B3GNT6 can help identify residues critical for substrate binding and catalysis, providing insights into the enzyme mechanism.
Knock-in
Knock-in of a tagged version of B3GNT6 (e.g., GFP or FLAG) enables tracking of enzyme localization and interaction partners in live cells, revealing its subcellular distribution.
Overexpression
Overexpression of B3GNT6 in cancer cell lines that lack endogenous activity can restore core 3 O-glycan synthesis and reverse some malignant phenotypes, helping establish causality.
How EDITGENE Supports acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity Research
Researchers studying acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in core 3 O-glycan synthesis, cancer progression, or epithelial barrier function. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity research.
Frequently Asked Questions About acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity
What is GO:0047224?
GO:0047224 is a molecular function term describing the enzymatic activity that transfers N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to a GalNAc residue already attached to a protein, forming a beta-1,3 linkage and creating the core 3 O-glycan structure.
What does acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase do?
It catalyzes the addition of GlcNAc to GalNAc-O-Ser/Thr on proteins, a key step in mucin-type O-glycan biosynthesis.
Which gene encodes core 3 beta3-GlcNAc-transferase?
The B3GNT6 gene encodes the enzyme responsible for this activity, although other related beta-1,3-N-acetylglucosaminyltransferases may also contribute.
What is the reaction catalyzed by GO:0047224?
The reaction is: 3-O-N-acetyl-D-galactosalaminyl-[protein] + UDP-N-acetyl-D-glucosamine = 3-O-N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-D-galactosaminyl-[protein] + UDP.
Where is this enzyme active?
It is highly active in colonic mucosa and other epithelial tissues, but its activity is often lost in cancer cell lines.
How is core 3 O-glycan synthesis regulated?
It is regulated by tissue-specific expression of B3GNT6, competition with other glycosyltransferases like C1GALT1, and availability of UDP-GlcNAc.
What diseases are associated with loss of core 3 O-glycans?
Loss of core 3 O-glycans has been linked to colon cancer and potentially other cancers, as well as inflammatory conditions.
How can I study GO:0047224 in the lab?
Common methods include enzymatic assays with radiolabeled UDP-GlcNAc, mass spectrometry of O-glycans, CRISPR knockout of B3GNT6, and lectin staining.
What is the difference between core 3 and core 1 O-glycans?
Core 1 is Gal-beta-1,3-GalNAc, while core 3 is GlcNAc-beta-1,3-GalNAc; they are synthesized by different enzymes and have distinct tissue distributions.
Can CRISPR be used to study core 3 O-glycosylation?
Yes, CRISPR knockout, knock-in, and overexpression of B3GNT6 and related genes are powerful approaches to dissect the function of GO:0047224.
Conclusion
GO:0047224 represents a critical enzymatic activity in the synthesis of core 3 O-glycans, which play important roles in mucin biology, epithelial protection, and cancer. Biochemical studies have characterized the enzyme in colonic mucosa and revealed its loss in cancer cell lines, highlighting its potential as a tumor suppressor. Continued research using CRISPR-based models will further elucidate its regulation and therapeutic potential.
References
- 1. Brockhausen I et al.. 1985. Mucin synthesis. UDP-GlcNAc:GalNAc-R beta 3-N-acetylglucosaminyltransferase and UDP-GlcNAc:GlcNAc beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase from pig and rat colon mucosa.. Biochemistry 24(8):1866-74 PMID: 3160388
- 2. Vavasseur F et al.. 1995. Synthesis of O-glycan core 3: characterization of UDP-GlcNAc: GalNAc-R beta 3-N-acetyl-glucosaminyltransferase activity from colonic mucosal tissues and lack of the activity in human cancer cell lines.. Glycobiology 5(3):351-7 PMID: 7655172
